Current and emerging therapies for metastatic colorectal cancer: Applying research findings to clinical practice

American Journal of Health-System Pharmacy

Volumn 65, Issue 11 SUPPL. 4, 2008, Pages

  Hecht, J Randolph ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antibodies; Antineoplastic agents; Bevacizumab; Cetuximab; Colorectal neoplasms; Combined therapy; Fluorouracil; Irinotecan; Leucovorin; Neoplasms metastasis; Oxaliplatin; Panitumumab; Site of action

Indexed keywords

AP 23573; BEVACIZUMAB; CAPECITABINE; CELECOXIB; CETUXIMAB; CP 751871; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EVEROLIMUS; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IMCA 12; IRINOTECAN; MAMMALIAN TARGET OF RAPAMYCIN; MONOCLONAL ANTIBODY; OXALIPLATIN; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PROTEIN TYROSINE KINASE; SOMATOMEDIN C; TEMSIROLIMUS; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADD ON THERAPY; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL TRIAL; COLORECTAL CANCER; CONFERENCE PAPER; DRUG APPROVAL; DRUG BINDING; DRUG EFFICACY; DRUG INHIBITION; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; METASTASIS; PRIORITY JOURNAL; SURVIVAL TIME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 44449113251     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp080102     Document Type: Conference Paper

References (46)

1. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Colon Cancer version 1.2007. http://www.nccn.org/professionals/ physician_gls/PDF/colon.pdf (accessed 2007 Feb 15).
2. Lokich JJ, Ahlgren JD, Gullo JJ et al. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. J Clin Oncol. 1989; 7:425-32.
3. Haller DG, Cassidy J, Clarke S et al. Tolerability of fluoropyrimidines appears to differ by region. J Clin Oncol. 2006; 24(18S suppl):abstract 3514.
4. Saltz LB, Cox JV, Blanke CB et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000; 343:905-14.
5. de Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000; 18:2938-47.
6. Grothey A, Sargent D, Golderg RM et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol. 2004; 22:1209-14.
7. Goldberg RM, Sargent DJ, Morton RF et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004; 22:23-30.
8. Tournigand C, Andre T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004; 22:229-37.
9. Cassidy J, Clarke S, Diaz-Rubio E et al. XELOX vs. FOLFOX4: efficacy results from XELOX-1/NO 16966, a randomized phase III trial in first-line metastatic colorectal cancer (MCRC). Presented at 2007 American Society of Clinical Oncology Gastrointestinal Cancers Symposium. Abstract 270.
10. Cassidy J, Clarke S, Diaz-Rubio E et al. First efficacy and safety results from XELOX-I/NO169966, a randomized 2X2 factorial phase III trial of XELOX vs. FOLFOX4 + bevacizumab or placebo in first-line metastatic colorectal cancer (MCRC). Presented at 31st European Society for Medical Oncology Congress. Istanbul, Turkey; October 2, 2006. Ann Oncol. 2006; 17(suppl 9):abstract LBA3.
11. Avastin package insert. South San Francisco, CA: Genentech, Inc.; 2006 Oct.
12. Gordon MS, Margolin K, Talpaz M et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol. 2001; 19:843-50.
13. Kabbinavar F, Hurwitz HI, Fehrenbacher L et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 2003; 21:60-5.
14. Kabbinavar FF, Schulz J, McCleod M et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol. 2005; 23:3697-705.
15. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350:2335-42.
16. Hochster HS, Hart LL, Ramanathan RK et al. Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): final analysis of the TREE-Study. J Clin Oncol. 2006; 24(18S suppl):abstract 3510.
17. Hecht JR, Trarbach T, Jaeger E et al. A randomized, double-blind, placebo-controlled, phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK222584 or placebo (CONFIRM-1). J Clin Oncol. 2005; 23(16S suppl):abstract 3.
18. Giantonio BJ, Catalano PJ, Meropol NJ et al. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200. J Clin Oncol. 2005; 23(16S suppl):abstract 2.
19. Fuchs C, Marshall J, Mitchell E et al. A randomized trial of first-line irinotecan/fluoropyrimidine combinations with or without celecoxib in metastatic colorectal cancer (BICC-C). J Clin Oncol. 2006; 24(18S suppl):abstract 3506.
20. Erbitux package insert. Princeton, NJ: Bristol-Myers Squibb Company; 2006 Mar.
21. Vectibix package insert. Thousand Oaks, CA: Amgen Inc.; 2006 Sep.
22. Venook A, Niedzwiecki D, Hollis D et al. Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) ± cetuximab for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (MCRC): CALGB 80203 preliminary results. J Clin Oncol. 2006; 24(18S suppl):abstract 3509.
23. PACCE: Panitumumab Advanced Colorectal Cancer Evaluation study. http://clinicaltrials.gov/ct/show/NCT00115765 (accessed 2007 Feb 20).
24. Hecht JR. Ann Oncol. 2007; 18(suppl 7):vii21.
25. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004; 351:337-45.
26. Saltz L, Rubin M, Hochster H et al. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol. 2001; 20:abstract 7. http://www.asco.org/portal/site/ASCO/menuitem. 34d60f5624ba07fd506fe310ee37a01d/?vgnextoid= 76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID= 10&abstractID=7 (accessed 2007 Feb 17).
27. Saltz LB, Meropol NJ, Loehrer PJ Sr et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol. 2004;22:1201-8.
28. Eng C, Maure J, Scheithauer W et al. Impact on quality of life of adding cetuximab to irinotecan in patients who have failed prior oxaliplatin-based therapy: the EPIC trial. J Clin Oncol. 2007; 25(18S suppl):4003.
29. Hecht JR, Pannaik A, Malik I et al. ABX-EGF monotherapy in patients (pts) with metastatic colorectal cancer (mCRC): an updated analysis. J Clin Oncol. 2004; 22(14S suppl):abstract 3511.
30. Van Cutsem E, Peeters M, Siena S et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 2007; 25(13):1658-64.
31. Peeters M, Van Cutsem E, Siena S et al. A phase 3, multicenter, randomized controlled trial (RCT) of panitumumab plus best supportive care (BSC) vs BSC alone in patients (pts) with metastatic colorectal cancer (mCRC). Presented at American Association for Cancer Research Annual Meeting. Washington, DC; 2006 Apr 3. Abstract CP-1.
32. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971; 285:1182-6.
33. Granville CA, Memmott RM, Gills JJ et al. Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway. Clin Cancer Res. 2006; 12:679-89.
34. Tabernero J, Rojo F, Calvo E et al. Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase 1 tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol. 2008; 26: 1603-10.
35. Serrels A, Macpherson IR, Evans TR et al. Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib. Mol Cancer Ther. 2006; 5:3014-22.
36. Stempelj M, Kedinger M, Augenlicht L et al. Essential role of the JAK/STAT1 signaling pathway in the expression of inducible nitric-oxide synthase in intestinal epithelial cells and its regulation by butyrate. J Biol Chem. 2007; 282(13):9797-804. Epub 2007 Jan 24.
37. Sprycel package insert. Princeton, NJ: Bristol-Myers Squibb Company; 2006 Jul.
38. Nosho K, Yamamoto H, Taniguchi H et al. Interplay of insulin-like growth factor-II, insulin-like growth factor-I, insulin-like growth factor-I receptor, COX-2, and matrix metalloproteinase-7, play key roles in the early stage of colorectal carcinogenesis. Clin Cancer Res. 2004; 10:7950-7.
39. Peruzzi F, Prisco M, Dews M et al. Multiple signaling pathways of the insulin-like growth factor 1 receptor in protection from apoptosis. Mol Cell Biol. 1999; 19:7203-15.
40. Cohen BD, Baker DA, Soderstrom C et al. Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res. 2005; 11:2063-73.
41. Duffaud F, Blay JY. Gastrointestinal stromal tumors: biology and treatment. Oncology. 2003; 65:187-97.
42. Valabrega G, Montemurro F, Giordano S et al. Non-linear relationship between HER-2 expression and response to trastuzumab in breast cancer cells. J Clin Oncol. 2006; 24(18S suppl):abstract 13083.
43. Berlin J, Neubauer M, Swanson P et al. Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing ≥ 10% epidermal growth factor receptor (EGFr). J Clin Oncol. 2006; 24(18S suppl):abstract 3548.
44. Malik I, Hecht JR, Patnaik A et al. Safety and efficacy of panitumumab monotherapy in patients with metastatic colorectal cancer (mCRC). J Clin Oncol. 2005; 23(16S suppl):abstract 3520.
45. Sjöblom T, Jones S, Wood LD et al. The consensus coding sequences of human breast and colorectal cancers. Science. 2006; 314:268-74.
46. Wilson CA, Dering J. Recent translational research: microarray expression profiling of breast cancer - beyond classification and prognostic markers? Breast Cancer Res. 2004; 6:192-200.